Introduction {#s1}
============

Anorexia nervosa (AN) is characterized by problems with eating, weight, and shape. Shape and weight concerns often involve social contagion and social evaluation [@pone.0090721-AllisonWarinBastiampillai1] and fat talk, teasing, and bullying often trigger the onset of the illness [@pone.0090721-Sharpe1], [@pone.0090721-Menzel1]. In addition, social difficulties may occur early in the development. Gillberg (1992) suggested an association between developmental traits such as low empathy and a later risk of developing an eating disorder [@pone.0090721-Gillberg1]. Patients with eating disorders, particularly those with AN, start showing signs of social difficulties before the actual onset of the illness [@pone.0090721-Krug1], and social problems at age 8 strongly predict eating disorder onset at age 14 [@pone.0090721-Allen1]. These social difficulties become more exaggerated during the illness leading to interpersonal problems and/or isolation [@pone.0090721-Treasure1]. A medical practitioner elaborated on the lack of social skills in AN by saying that if she had to use one word to describe what she saw in her patients with AN, it would be "isolation" [@pone.0090721-McKnight1]. Loneliness and social exclusion heighten sensitivity to social threats, increase depressive symptomatology, and aggravate many of the psycho-physiological consequences of stress and chronic inflammation [@pone.0090721-Cacioppo1]. Social exclusion in primates is associated with a variety of critical metabolic consequences, including reduced levels of oxytocin [@pone.0090721-Michopoulos1]. These studies suggest that social factors may be contributing to the causal and the maintenance factors of AN [@pone.0090721-Treasure1], [@pone.0090721-Arcelus1].

The social processing problems in patients with eating disorders have been synthesized in recent systematic reviews, and impairments in emotional recognition, social hierarchy, and theory of mind have been found [@pone.0090721-Oldershaw1]--[@pone.0090721-CorfieldCardiLeppanenRhindDeriziotis1]. Additionally, patients with AN display less facial emotional expression, to either emotionally salient films or to challenging situations, while showing high levels of emotion on self-report measures [@pone.0090721-Davies1], [@pone.0090721-Claes1]. Some of these difficulties in social and emotional functioning include problems with attentional processing. Patients with AN (in both acute and recovered states) have an attentional bias towards rejecting criticism and away from accepting positive facial expressions [@pone.0090721-Cardi1]. This observation suggests that patients with AN are sensitized to socially evaluative threats and are less responsive to social rewards.

Oxytocin is an important neuromodulatory hormone involved in social emotional processing, particularly in association with attentional processes. Oxytocin increases the sensitivity to detect emotional expressions, which is associated with recruitment of attentional resources, as evidenced by pupil dilation [@pone.0090721-Prehn1]. Oxytocin also enhances evaluative processing of both explicit and hidden positive and negative facial expressions [@pone.0090721-Leknes1]. Oxytocin modulates the attention paid to threat and reward. Rhesus monkeys, when given oxytocin, pay less attention to threatening facial expressions [@pone.0090721-Parr1]. In humans, oxytocin reduces eye gaze to angry expressions [@pone.0090721-Domes1], and in healthy females, oxytocin increases amygdala reactivity to both social and non-social threats [@pone.0090721-Lischke1]. In contrast, in women with borderline personality disorder, oxytocin decreases early eye gaze and amygdala reactivity to social threats [@pone.0090721-Bertsch1]. A study using the dot probe paradigm found an avoidant pattern to threat but this pattern was normalized when oxytocin was administered [@pone.0090721-BruneEbertKolbTasEdel1]. Oxytocin also increases eye gaze to happy expressions in human [@pone.0090721-Domes1], [@pone.0090721-Tollenaar1] and early attention to happy faces in young men [@pone.0090721-Domes2]. However other studies have found that oxytocin does not influence detection of positive emotion (happiness) [@pone.0090721-Guastella1], [@pone.0090721-KimOhCorfieldJeongJang1]. In summary, when the analyses were restricted to facial expression types, significant effects of oxytocin on recognition accuracy were specifically found for recognition of happy and fear faces [@pone.0090721-Shahrestani1]. Although there are individual and perhaps gender differences in attentional processes (avoidance vs. vigilance), the overall effect of oxytocin is that it decreases attention to threat and increases attention to happiness.

It is possible that changes in oxytocin function may account for some of the anomalies in social cognition in patients with AN. A recent review synthesized evidence for abnormal oxytocin functioning in patients with AN [@pone.0090721-Maguire1]. Cerebrospinal fluid levels of oxytocin decrease during the starvation phase of AN [@pone.0090721-Chiodera1]--[@pone.0090721-Lawson1]. Nocturnal serum oxytocin levels in patients with AN are also reduced [@pone.0090721-Lawson2]. Lawson et al. [@pone.0090721-Lawson1] reported that the release of oxytocin increases in response to a meal in the acute state of AN and decreases after recovery. Abnormalities in oxytocin secretion are correlated with severity of the disordered eating psychopathology and with the level of activation of trait anomalies in oxytocin function in the brain circuitry in patients with AN. Therefore, it is of interest to examine whether oxytocin moderates some of the social processing problems in patients with AN.

The aim of this study was to examine whether oxytocin impacts on social attentional processes in patients with AN. Our first hypothesis, based on previous studies using the dot probe paradigm, is that patients with AN would have vigilance towards threatening cues and away from rewarding stimuli. Our second hypothesis is that oxytocin would attenuates the selective attention towards negative social cues.

Methods {#s2}
=======

Participants {#s2a}
------------

Sixty-four women (31 patients with AN and 33 healthy university students) took part in this double-blind, placebo-controlled cross-over study. The first participant entered the study on August 16, 2012, and the last participant was examined on November 30, 2013. The patients with AN were recruited at the Eating Disorders Clinic of Seoul Paik Hospital, Seoul, South Korea. As this study aimed to examine broadly whether oxytocin might be of benefit in the short term for patients with AN, patients were recruited at various stages and phase of illness both from an outpatient clinic (n = 13) and an inpatient ward (n = 18). All patients who volunteered to participate were screened during the early phase of treatment. All of them were in an active stage of illness, and none of them were in the weight-recovered stage. The diagnosis of AN was confirmed by the Structured Clinical Interview from the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [@pone.0090721-First1]. Exclusion criteria for patients were: active substance use disorder, diagnosis of a psychotic disorder (schizophrenia, schizoaffective, psychosis not otherwise specified), diagnosis of autism or Asperger\'s syndrome. All other comorbid diagnoses were allowed. Patients taking any psychiatric medications influencing attentional bias were excluded [@pone.0090721-Murphy1], although three patients who had been taking a stable low dose (20 mg/d) of fluoxetine for several weeks were included. The participants in the comparison group were undergraduate or graduate students who had responded to an advertisement posted in the psychology department at a women\'s university in Seoul, South Korea. The inclusion criteria were: healthy females without a history of medical or psychiatric illnesses and a minimum of 18 years old. All subjects were postpubertal, nonsmokers, heterosexual, nulliparous, and were not taking any medications (including the contraceptive pill). Exclusion criteria included a self-reported history of major depression, bipolar, panic, or psychotic disorders, substance dependence, epilepsy, eating disorders, autism spectrum disorder, or traumatic brain injury.

The Korean version of the Wechsler Adult Intelligence Scale was used to measure IQ. Healthy participants were tested during the follicular phase of their menstrual cycle. None of the patients were menstruating. Compensation was provided for travelling expenses and time. This study protocol was approved by both the Korean Food and Drug Association Institutional Review Board (12061) and the Institutional Review Board of Seoul Paik Hospital (IIT-2012-096). All participants provided written informed consent prior to participating in the study. Consent was provided by both the patients and their guardians in the case of 16-year-old patients.

Oxytocin preparation {#s2b}
--------------------

The intranasal oxytocin spray was formulated by *JW* Pharmaceuticals (Seoul, South Korea) from oxytocin powder (Hemmo Pharmaceuticals, Mumbai, India). The solution was prepared by combining 35.2 mg oxytocin (568 U) with 300 mL 0.9% sodium chloride solution, and adjusting the pH to 4.01 with 10× diluted acetic acid. The placebo spray (pH 4.01) was formulated with 0.9% sodium chloride solution and acetic acid, but without the peptide. The filtered and sterilized solution was sealed in individual vials (1.5 mL each) and stored frozen. On the day of use, the vials were thawed and kept in a refrigerator (4°C) until required. A clinician prepared the nasal spray by transferring oxytocin or the placebo from the vial into a nebulizer.

Oxytocin or placebo administration {#s2c}
----------------------------------

Oxytocin and the placebo were administered intranasally 4--7 days apart 45 min before the neuropsychological tasks. We chose a dose of 40 IU of oxytocin based on a recent review reporting that cumulative evidence from clinical trials shows that short-term use of intranasal oxytocin administered to both male and female humans in dosages up to 40 IU (per dose) results in no detectable subjective adverse effects in a controlled research setting [@pone.0090721-MacDonald1]. Each participant was randomized in a double-blind manner to either receive oxytocin or the placebo first (neither the researcher nor the participant knew the group assignments). At the start of day 1, the participants were asked to self-administer the spray containing either oxytocin or the placebo while being monitored by a clinician under supervision of the project coordinator. On day 2, each participant self-administered the spray they had not received on day 1 according to the cross-over design.

Visual probe task {#s2d}
-----------------

### Stimuli {#s2d1}

The photographic stimuli used for the dot probe task were obtained from a validated collection of the Korean Facial Expressions of Emotions (KOFEE) [@pone.0090721-Park1]. The photos consisted of a pool of adult facial expressions that might provoke emotional responses. The pool was based on Ekman and Friesen\'s Facial Action Coding System [@pone.0090721-Ekman1]. Actors and actresses for the photos were introduced to different emotions with characteristic facial muscle contractions and were requested to perform facial muscle movements according to the directed facial actions for each emotion while the photographs were obtained. Our candidate negative emotions for this study were disgust and anger, as these emotions result in quicker detection of attentional bias and avoidance [@pone.0090721-GilboaSchechtman1].

Our pool of target stimuli consisted of 60 images of adults showing 15 positive (happy) or 30 negative (15 angry and 15 disgust) expressions, with each adult having a corresponding picture showing a neutral expression (15 non-target stimuli). The target stimuli were paired with matched non-target stimuli.

### Design and procedure {#s2d2}

Attentional biases were assessed using a visual probe detection task [@pone.0090721-Posner1] displaying pairs of pictures \[target (emotional) and non-target (neutral)\] [@pone.0090721-Macleod1]. Participants were shown a centrally positioned fixation cross for 750 ms, which was replaced by target (i.e., emotional) and non-target (i.e., neutral) pictures for 1,000 ms, following the paradigm of Mansell et al. [@pone.0090721-Mansell1].

As the two images disappeared from the screen, one of two probes (':' or '..') appeared where used to be the center of one of the two pictures. The participants were required to press one of two buttons on a keyboard (marked with white stickers) that corresponds to the probe (Q for ':' and Z for '..'). When a response was made, the probe disappeared and the next trial started. Participants were advised to identify the probe as quickly and accurately as possible. The target stimuli positions and the probe positions were balanced across trials, so each appeared in either location (right or left; probe behind the target or non-target) with equal frequency, following the paradigm of Mogg and Bradley [@pone.0090721-Mogg1]. After a response was made, the probe disappeared, and the next trial started immediately.

Attention during the visual probe detection task was measured as the time to respond to the probe. The assumption is that the time to respond to the probe is faster if attention was already allocated to the spatial location where the probe appeared. Faster responses to congruent trials (when the probe emerges at the threatening stimulus location) compared to incongruent trials (when the probe emerges at the neutral stimulus location) were interpreted as vigilance to a threat.

These tests were comprised of 10 trials in each of six conditions: three target stimuli (happy, angry, and disgust) and two probe locations (the location of the target stimuli or non-target stimuli), for a total of 60 trials, repeated twice. Test trials were presented in a new random order for each participant. The dot-probe task was presented on E-prime ver. 2 (Psychology Software Tools, Inc., Pittsburgh, PA, USA).

Objective psychological measures {#s2e}
--------------------------------

### The Eating Disorder Examination (EDE) interview [@pone.0090721-Heo1], [@pone.0090721-Fairburn1] {#s2e1}

The Korean version of the clinician rating interview of the EDE [@pone.0090721-Heo1], [@pone.0090721-Fairburn1] was conducted with the patients with AN to establish the degree of eating psychopathology. The Korean version of the EDE has good demonstrated inter-rater reliability (Pearson\'s correlation coefficients  = 0.98--1.0) and internal consistency (Cronbach\'s alpha  = 0.72--0.89) for variables [@pone.0090721-Fairburn1].

Self-report measures {#s2f}
--------------------

### Eating Disorder Examination self-report version Questionnaire (EDE-Q) [@pone.0090721-Fairburn2] {#s2f1}

The EDE-Q assesses the main behavioral features of an eating disorder over the past 28 days. The questionnaire consists of 36 items on a 7-point forced choice rating scale. It measures weight, shape, eating concerns, and dietary restraint. We used the standardized Korean version of the 12th edition of the EDE-Q, which has high internal consistency and good 2 week reliability.

### State-Trait Anger Expression Inventory (STAXI) [@pone.0090721-Spielberger1] {#s2f2}

The STAXI is a 44-item self-report questionnaire that is divided into seven scales. It measures the current intensity of anger (State Anger) and disposition toward anger as a personality trait (Trait Anger) and the tendency to express anger when criticized (Angry Reaction). The other scales measure the frequency with which provoked anger is suppressed (Anger-Suppression), the frequency of the expression of anger toward other people or objects (Anger-Expression), and the frequency at which the expression of anger is controlled (Anger-Control). The Korean version of the STAXI was used in this study [@pone.0090721-Chon1] and has good reliability.

### Autism-Spectrum Quotient (AQ) [@pone.0090721-BaronCohen1] {#s2f3}

The AQ is a 50-item, self-administered questionnaire that assesses the degree to which adults with normal intelligence have autism spectrum traits. It has five sub-scales, including social skill, attention switching, attention to detail, communication, and imagination.

### Other measurements {#s2f4}

Depression and anxiety were assessed in each subject using the standardized Korean versions of the Beck Depression Inventory (BDI) [@pone.0090721-Beck1] and the Spielberger State and Trait Anxiety Inventory (STAI) [@pone.0090721-Spielberger2], respectively.

Procedures {#s2g}
----------

The participants were tested in a private room at Seoul Paik Hospital. They were instructed to abstain from alcohol and caffeine on the day of drug administration and food and drink (other than water) for 2 hours before drug administration. Upon arrival, the participants completed baseline measures of physical symptoms, including abdominal, neurological, dermatological, and cardiac symptoms. Subsequently, oxytocin or the placebo was self-administered by inhalation of the spray into each nostril. The order of oxytocin and placebo administration was randomized using Microsoft Excel in this double-blind procedure. The participants completed the self-report measures to assess their psychological state during the 45 minutes after administration of each spray. At the end of the study period, each participant completed follow-up measures for adverse physical symptoms.

Statistical analysis {#s2h}
--------------------

We followed the standard analysis procedure used for this task [@pone.0090721-Bradley1]. Only the trial reaction times (RT) for correct responses were included. The correct response rates were 96.1% for the AN group and 97.7% for the healthy control (HC) group. Mean RTs were calculated for each participant. Outliers were removed by excluding detection latencies that were beyond two standard deviations from their mean (i.e. from each individual\'s mean RTs across all stimuli).

Attentional bias scores were calculated for each matched trial type (happy-neutral, angry-neutral, disgust-neutral) as PN − PE, where PN is the mean RT for probes replacing neutral stimuli, and PE is the mean RT for probes replacing emotional target stimuli. Therefore, positive scores suggest increased attention towards the emotional/target stimuli, whereas negative scores indicate attention away from emotional/target stimuli. A score of 0 suggests no bias towards any stimuli.

The attentional responses to shape stimuli were investigated via a series of initial 2 (group: AN and HC) ×2 (drug: oxytocin and placebo) ×3 (valence: happy, angry, disgust) repeated-measures analyses of variance (ANOVAs). Post-hoc analyses were conducted through paired *t*-test comparisons for each group. Greenhouse--Geisser corrections were applied on the assumption that sphericity was violated. Data are shown as mean and with the effect size (ES) if appropriate \[Cohen\'s *d* for t-tests; partial eta square (Δη^2^) for ANOVA\]. The estimation of ES was based on Cohen\'s *d*: described as negligible ( = 0 and \<0.15), small (≥0.15 and \<0.40), medium (≥0.40 and \<0.75), large (≥0.75 and \<1.10), very large (≥1.10 and \<1.45) and huge (\>1.45) (Cohen, 1992). We defined the drug effect as the difference in the RT score between the administration of the placebo and oxytocin (drug effect  =  RT~placebo~ − RT~oxytocin~). Pearson\'s correlations were used to investigate the relationship between the drug effect on attentional bias and psychological variables. Analyses were performed using SPSS 19.0 (SPSS Inc., Chicago, IL, USA), and the two-tailed p-value was 0.05.

Results {#s3}
=======

Demographic and group characteristics {#s3a}
-------------------------------------

The demographic and the group characteristics of the participants are shown in [Table 1](#pone-0090721-t001){ref-type="table"}. The mean age and IQ were similar between the AN and the control groups. As expected, significant differences were observed in body mass index (BMI, kg/m^2^) and the EDE-Q scales. The AN group also scored significantly higher on the BDI, STAI, and the Social Skill, Attention, and Communication subscales and the total score on the AQ compared to those in the HC group. The EDE interview scores of the AN group were 5.07±6.04 for the restraint subscale, 3.73±4.41 for the eating concern subscale, 4.35±8.33 for the weight concern subscale, and 3.85±3.10 for the shape concern subscale.

10.1371/journal.pone.0090721.t001

###### Demographic and group characteristics.

![](pone.0090721.t001){#pone-0090721-t001-1}

                         AN (*n* = 31)    Control (*n* = 33)        *t*         *df*      *p*
  --------------------- ---------------- -------------------- ---------------- ------- ---------
  Age                     23.10 (9.35)       22.18 (2.14)          −0.536       32.87    0.596
  Intelligence           109.27 (14.01)     114.62 (9.05)          1.788        48.51    0.080
  BMI                     15.15 (2.51)       20.91 (2.22)      9.819^\*\*\*^     62     \<0.001
  EDE-Q                                                                                
  Restraint               2.50 (1.89)        0.79 (0.86)       −4.558^\*\*\*^   39.31   \<0.001
  Eating Concern          2.10 (1.80)        0.55 (0.76)       −4.388^\*\*\*^   38.14   \<0.001
  Weight Concern          2.63 (1.61)        1.46 (1.13)        −3.330^\*\*^    51.06    0.002
  Shape Concern           3.01 (1.56)        2.14 (1.31)         −2.435^\*^      62      0.018
  Global                  2.56 (1.56)        1.23 (0.89)       −4.120^\*\*\*^   44.91   \<0.001
  AQ                                                                                   
  Social Skill            3.94 (1.93)        2.67 (1.81)        −2.710^\*\*^     62      0.009
  Attention Switching     4.52 (1.93)        4.21 (1.36)           −0.724       53.67    0.472
  Attention to Detail     5.03 (2.23)        3.97 (2.08)           −1.971        62      0.053
  Communication           2.73 (1.82)        1.58 (1.35)        −2.848^\*\*^    53.17    0.006
  Imagination             2.29 (1.88)        2.12 (1.50)           −0.399        62      0.691
  Total                   18.60 (5.33)       14.55 (4.28)       −3.344^\*\*^     62      0.001
  BDI                    24.53 (14.01)       7.38 (6.89)       −6.057^\*\*\*^   41.64   \<0.001
  STAI                                                                                 
  State                  58.47 (13.13)      43.28 (11.25)      −4.899^\*\*\*^    62     \<0.001
  Trait                  57.53 (13.46)      43.75 (11.33)      −4.371^\*\*\*^    62     \<0.001
  STAXI                                                                                
  Anger_state            16.13 (10.10)       11.66 (5.01)        −2.189^\*^     41.87    0.034
  Anger_trait             21.20 (7.76)       18.22 (5.96)          −1.703        60      0.094
  Anger_suppression       17.10 (4.77)       17.97 (4.31)          0.753         60      0.455
  Anger_expression        16.17 (3.85)       15.22 (3.85)          −0.969        60      0.337
  Anger_control           17.83 (5.37)       19.72 (4.76)          1.465         60      0.148

AN, anorexia nervosa; BMI, body mass index; AQ, autism-spectrum quotient; STAI: Spielberger State-Trait Anxiety Inventory; STAXI, State and the Trait Anger Expression Inventory.

Data are shown as mean (standard deviation). \**p*\<0.05, \*\**p*\<0.01, \*\*\**p*\<0.001.

Attentional bias for emotional faces using the visual attention task {#s3b}
--------------------------------------------------------------------

A significant group x drug x emotion interaction effect (*F*(2,124)  = 3.568, *p* = 0.031, Δ*η^2^*  = 0.057) was observed in the three-way group (AN vs. HC) × drug (oxytocin vs. placebo) × emotion (happy, angry, disgust) repeated-measures ANOVA.

The two-way group (AN vs. HC) × drug (oxytocin vs. placebo) repeated-measures ANOVA identified a group × drug interaction effect (*F*(1,62)  = 4.988, *p* = 0.029, Δ*η^2^*  = 0.078).

The attentional bias scores across conditions in each group are shown in [Table 2](#pone-0090721-t002){ref-type="table"}.

10.1371/journal.pone.0090721.t002

###### Attentional bias scores in response to happy, angry, or disgusted faces from the visual dot probe task in either the oxytocin or placebo condition in patients with anorexia nervosa and healthy controls.

![](pone.0090721.t002){#pone-0090721-t002-2}

               AN (n = 31)      HC (n = 33)                                                                                           
  --------- ----------------- ---------------- -------------- ------- -------- --------------- ---------------- ------------- ------- --------
  Happy       −0.66 (84.92)     3.16 (73.15)       −0.168      0.868   −0.048   1.05 (66.34)     1.94 (61.03)      −0.057      0.955   −0.014
  Angry      −38.27 (104.70)   48.00 (117.90)   −2.847^\*\*^   0.008   −0.774   25.38 (97.73)   −3.29 (77.66)       1.218      0.233   0.325
  Disgust    24.34 (100.73)    −16.38 (94.05)      1.602       0.120   0.408    21.90 (60.48)   −38.26 (79.99)   3.138^\*\*^   0.004   0.848

AN, anorexia nervosa; HC, healthy control.

Data are shown as mean (standard deviation) \**p*\<0.05, \*\**p*\<0.01.

The two-way group (AN vs. HC) × drug (oxytocin vs. placebo) repeated-measures ANOVA showed that there was neither a main effect of drug (*F*(1,62)  = 0.028, *p* = 0.868, Δ*η^2^*  = 0.000) nor a group × drug interaction effect in response to happy stimuli (*F*(1,62)  = 0.009, *p* = 0.925, Δ*η^2^*  = 0.000).

The two-way group (AN vs. HC) × drug (oxytocin vs. placebo) repeated-measures ANOVA showed that there was a group × drug interaction effect (*F*(1,62)  = 8.970, *p* = 0.004, Δ*η^2^*  = 0.130) in response to the angry stimuli. Post-hoc tests showed avoidance of angry faces in the AN group and vigilance in the HC group with a moderate to large difference between the AN and HC groups under the placebo condition (*t*(62)  = 2.510, *p* = 0.015, *d* = −0.633). Both of these information processing responses were moderated by oxytocin and produced a large increase in vigilance in the AN group (*t*(30)  = −2.847, *p* = 0.008, *d* = 0.785) but a tendency to decrease with a small ES in attention in the HC group (*t*(32)  = 1.218, *p* = 0.233, *d* = 0.219).

The two-way group (AN vs. HC) × drug (oxytocin vs. placebo) repeated-measures ANOVA showed a main effect of drug (*F*(1,62)  = 10.120, *p* = 0.002, Δ*η^2^*  = 0.142) with no group × drug interaction effect (*F*(1,62)  = 0.375, *p* = 0.542, Δ*η* ^2^  = 0.006) in response to the disgust stimuli. Post-hoc tests showed an attentional bias to the disgust stimuli in both the AN and HC groups under the placebo condition (*t*(62)  = 3.208, *p* = 0.002, *d* = 0.597). Attentional bias was reduced under the oxytocin condition in both groups with a small effect in the AN group (*t*(30)  = 1.602, *p* = 0.120, *d* = 0.418) and a moderate/large effect in the HC group (*t*(32)  = 3.138, *p* = 0.004, *d* = 0.555). The attentional bias scores across conditions in each group are shown in [Figure 1](#pone-0090721-g001){ref-type="fig"}.

![The effect of oxytocin on attentional bias to facial stimuli with happy, angry, or disgusted expressions in patients with AN and HC.\
Data are mean and standard error (AN, anorexia nervosa; HC, healthy control). Avoidance of angry faces was observed in the AN group and vigilance to them was observed in the HC group under the placebo condition; both of these responses were moderated by oxytocin. In particular, vigilance to anger significantly increased in the AN group (AN: *t*(30)  = −2.847, *p* = 0.008, *d* = −0.774; HC: *t*(32)  = 1.218, *p* = 0.233, *d* = 0.325). Attentional biases to the disgust stimuli were observed in both groups under the placebo condition. The attentional biases to disgust decreased under the oxytocin condition (AN: *t*(30)  = 1.602, *p* = 0.120, *d* = 0.418; HC: *t*(32)  = 3.138, *p* = 0.004, *d* = 0.848). No marked attention to happy faces was observed in either the placebo or oxytocin conditions.](pone.0090721.g001){#pone-0090721-g001}

Association between attentional biases and clinical variables {#s3c}
-------------------------------------------------------------

The reduced vigilance to angry stimuli in the HC group was positively correlated with STAXI subscales of anger expression in the oxytocin condition (*r* = 0.415, *p* = 0.023, *n* = 33) i.e., individuals with higher anger expression showed a greater reduction in vigilance with oxytocin. There was no association between STAXI subscales and the oxytocin effect on angry stimuli in patients with AN. No association was observed between the drug effect and aspects of psychopathology typically associated with eating disorders (EDE-Q), depression (BDI), state and trait anxiety (STAI), autism traits (AQ) in either the AN or HC groups. No association between BMI or weight and the oxytocin effect were observed in either the AN group (BMI/weight: *p* = 0.824/0.837 for happy faces, *p* = 0.164/0.353 for angry faces, *p* = 0.844/0.741 for disgust faces) or in the HC group (*p* = 0.646/0.964 for happy faces, *p* = 0.842/0.683 for angry faces, *p* = 0.991/0.898 for disgust faces).

Discussion {#s4}
==========

The aim of this study was to examine whether oxytocin had an impact on social attentional processes in patients with AN. Unlike our prediction, avoidance of, rather than vigilance to, angry faces was observed in the patients with AN under the placebo condition and vigilance to anger was observed in the HC. Vigilance to disgust was observed in both patients with AN and the HC group. Happy (smiling) faces produced no attentional bias in patients with AN or the HC group. Our second hypothesis was confirmed, in part, as oxytocin attenuated the selective attention towards disgust in both the patients with AN and the HC group. In contrast, oxytocin converted an avoidant response to anger into vigilance in patients with AN but reduced the vigilant response to anger in the HC group. Oxytocin did not change the lack of attention to happy (smiling) faces in either the AN or HC groups.

Our result that smiling faces did not produce an attentional bias in either the AN or HC groups was consistent with other findings in Caucasian patients with AN [@pone.0090721-CorfieldCardiLeppanenRhindDeriziotis1]. However, the same laboratory found that faces depicting warmth and acceptance using the stimulus set of Dandeneau, Baldwin, Baccus, Sakellaropoulo, and Pruessner produced attentional biases (avoidance in AN and vigilance in HC) [@pone.0090721-Cardi1]. Ekman [@pone.0090721-Ekman2] described many different types of smiles and distinguished the Duchenne smile [@pone.0090721-Ekman3], which communicates positive emotions, from other types of smiles, which may be aversive and processed as a threat by some individuals [@pone.0090721-Ekman4]. Thus, a more nuanced approach to stimulus sets of faces depicting social reward may be needed.

In the oxytocin condition, the attentional bias was away from disgusted faces in both groups with a larger effect in the HC group. To our knowledge no previous study has evaluated the impact of oxytocin on recognition of the disgust emotion in humans. The results are consistent with another study, which found that oxytocin decreases attention toward negative faces (i.e., sad) in healthy people [@pone.0090721-Ellenbogen1].

The avoidance response to anger expression in patients with AN and a vigilant response in the HC group under the placebo condition differed from a study that used "rejecting" facial expressions in which the opposite pattern was found, i.e., vigilance to the rejecting stimuli in patients with AN [@pone.0090721-Cardi1]. One interpretation of this difference is that rejecting faces have different implications than angry ones. Interestingly, when given oxytocin, patients with AN became vigilant to these cues, whereas vigilance in the healthy group diminished. Moreover, the response to oxytocin appeared to be moderated by the trait of higher anger expression. The decreased in attentional bias to angry stimuli in the HC group was associated with higher anger expression, whereas no association between increased vigilance to the angry face and STAXI subscales was observed in patients with AN. These findings suggest that patients with AN may use different strategies and circuits to regulate anger from those of healthy people. It has been suggested that patients with AN may have difficulties with anger, perceiving it as "toxic" and unacceptable, which may lead to anger suppression [@pone.0090721-Harrison1]. The pattern of directing anger and hostility inwardly in patients with AN is supported by previous studies [@pone.0090721-Geller1]--[@pone.0090721-Miotto1]. Women with AN have lower levels of anger expression than those with bulimia nervosa [@pone.0090721-Fassino1], and increased difficulties coping with anger and frustration are found in those with AN [@pone.0090721-Krug2]. The vigilant reaction of people with AN to anger cues under the oxytocin condition was more like the HC group in the placebo condition. This is coherent with the idea that the avoidance of emotional processing through self-starvation is a maladaptive coping strategy [@pone.0090721-Schmidt1].

These findings raise the possibility that oxytocin treatment may moderate some of these social difficulties and possibly improve the outcome. Resistance to treatment is associated with less activation in social cognition circuits within the brain [@pone.0090721-SchulteRuther1]. The vicious cycle of maintenance in patients with AN is self-perpetuated either through starvation or through feelings of low self-worth and/or fear of rejection [@pone.0090721-Aspen1]. The appropriate acknowledgment and expression of anger and frustration, through aggressive or assertive behavior, may be vital for functional social experience [@pone.0090721-Ochsner1].

There are some limitations in this study that need to be considered and which may account for some of the individual variation in this study. First, a third of the patients with AN were recruited from the outpatient clinic and the others were from the inpatient ward. So the patients were at different phases of treatment. The oxytocinergic pathway may differ in the more severely affected patients undergoing refeeding, compared to that of outpatients. However, all of our participants were screened when they initially visited to the clinic and were in the active stage of the illness, regardless of their inpatient or the outpatient status. None of them were weight-recovered. This is a proof of concept study which aimed to broadly examine that oxytocin might be of benefit in the short term across different stages. Further studies should consider controlling the illness stages. Second, the doses of intranasal oxytocin were not adjusted for individual differences in BMI and therefore the underweight patients received a higher doses per weight than healthy controls. However, in our subsidiary analysis, no relationship was observed between the BMI or weight and the oxytocin effect in either the AN or healthy control groups. Further studies examining for a dose relationship may be of interest and reduce the variance. Third, three patients took fluoxetine, which may affect the oxytocin pathway, so may have increased the variance. An additional analysis found no differences in the response of this subgroup to the non medicated patients. Finally, we did not measure other individual factors that are known to impact attention bias. For example, individuals with a short 5-hydroxytryptamine allele have been found to be more vigilant towards threat [@pone.0090721-PergaminHight1]. Additionally, the experience of childhood care, personality, and interpersonal context are known to influence the effects of oxytocin [@pone.0090721-BakermansKranenburg1].

In conclusion, patients with AN showed an avoidance of angry faces whereas healthy women were vigilant to anger in the placebo condition. This response in the AN group shifted from avoidance to vigilance following oxytocin administration but there was a trend for the healthy women to be less vigilant to angry faces. Patients with AN showed vigilance to faces of disgust similar to the healthy women and this was moderated with oxytocin in both groups reaching a significant effect in healthy women. Neither group had any attentional bias to happy faces under either the oxytocin or control conditions. These findings suggest that further evaluation of oxytocin nasal spray as a treatment to improve emotional processing and social communication particularly in relationship to anger may be of value in patients with AN.
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